Navigation Links
Microban International Announces Breakthrough in Antimicrobial Technologies for Medical Devices
Date:12/16/2010

HUNTERSVILLE, N.C., Dec. 16, 2010 /PRNewswire/ -- Hospital Acquired Infections (HAI's) are a serious health threat associated with over 100,000 deaths each year.  These secondary infections following surgery are a major contributor to increased healthcare costs; experts estimate they add in excess of $20 billion.

Microban International is leveraging its expertise in antimicrobial technologies for polymers to look for synergistic effects to help medical device manufacturers address bacterial contamination of medical devices commonly associated with HAI's.  "Our experience with a broad range of antimicrobial technologies and materials puts us in a unique position to be able to help medical device manufacturers get to market more quickly with more effective technologies," said Dr. Ivan Ong, VP of Research and Development for Microban International.

The company has recently made significant advances in the development of antimicrobial solutions for acetal (POM), a material commonly used in catheter tubing and connector components which can be a source of HAI's.  Acetals are prone to processing issues with many additives, causing chemical degradation and formaldehyde off-gassing in the final product.  A new antimicrobial solution has been developed that is compatible with acetal and causes no destabilization or formaldehyde generation.  Our findings show effective performance with greater than 4 log reductions against a wide variety of organisms using our standard, enhanced and human-serum based testing protocols.  "This new work is a significant step forward and will help medical device manufacturers to offer an antimicrobial solution that is more robust and provides more consistent antimicrobial performance," said Dr. Ong.  

Microban provides comprehensive development support and project management including engineering services, on-site microbiology, analytical efficacy testing and regulatory guidance.  For more information please visit http://www.microban.com/microban-medical.

Contact: Cady Warner, (704) 875-0806


'/>"/>
SOURCE Microban International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dal-Tile Corp. Launches Two New Lines of Ceramic Tile with Microban(R) Silver Antimicrobial Technology
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
4. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
5. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
6. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
7. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
8. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
10. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
11. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
Breaking Medicine News(10 mins):